A randomized, comparative, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 01 Oct 2013 Biomarkers information updated
- 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2008 Actual end date added as 1 Aug 2008 as reported by ClinicalTrials.gov.